Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update

Vivani Medical, Inc. (NASDAQ:VANI) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 401,264 shares, a growth of 87.4% from the January 15th total of 214,164 shares. Based on an average daily volume of 771,804 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.0% of the shares of the stock are short sold. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 771,804 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on VANI shares. Zacks Research upgraded Vivani Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

Vivani Medical Stock Performance

Shares of NASDAQ:VANI opened at $1.17 on Friday. The company has a market cap of $91.46 million, a P/E ratio of -2.60 and a beta of 3.11. Vivani Medical has a one year low of $0.91 and a one year high of $1.92. The business’s 50-day simple moving average is $1.34 and its 200 day simple moving average is $1.38.

Vivani Medical (NASDAQ:VANI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. Analysts predict that Vivani Medical will post -0.41 earnings per share for the current year.

Insider Transactions at Vivani Medical

In other Vivani Medical news, Director Gregg Williams bought 1,737,765 shares of Vivani Medical stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the transaction, the director owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have bought 6,564,645 shares of company stock valued at $7,943,155. 46.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vivani Medical

A number of institutional investors have recently added to or reduced their stakes in the company. Panagora Asset Management Inc. purchased a new position in Vivani Medical in the 2nd quarter valued at about $25,000. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical during the third quarter worth about $26,000. Susquehanna International Group LLP lifted its stake in shares of Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after acquiring an additional 16,200 shares in the last quarter. Jane Street Group LLC purchased a new position in Vivani Medical in the fourth quarter valued at about $60,000. Finally, Renaissance Technologies LLC boosted its holdings in Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the last quarter. Institutional investors and hedge funds own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.